Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVACT: CryptiVax-1001 in Advanced Ovarian Cancer
NCT07665515Phase 1Recruiting
- Sponsor
- Epitopea
- Start
- Sep 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of CryptiVax-1001 in ovarian cancer (6 arms), sponsored by Epitopea. Primary endpoint: Safety and Tolerability of CryptiVax-1001 up to 2 years. Started Sep 2026; status: recruiting.
02
Drugs
CryptiVax-1001
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07665515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07665515.